Philippe Busque - Cytek Biosciences Senior Services
| CTKB Stock | USD 5.16 0.16 3.20% |
Executive
Philippe Busque is Senior Services of Cytek Biosciences
| Age | 55 |
| Address | 47215 Lakeview Boulevard, Fremont, CA, United States, 94538 |
| Phone | 877 922 9835 |
| Web | https://cytekbio.com |
Philippe Busque Latest Insider Activity
Tracking and analyzing the buying and selling activities of Philippe Busque against Cytek Biosciences stock is an integral part of due diligence when investing in Cytek Biosciences. Philippe Busque insider activity provides valuable insight into whether Cytek Biosciences is net buyers or sellers over its current business cycle. Note, Cytek Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cytek Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Philippe Busque over six months ago Acquisition by Philippe Busque of 58004 shares of Cytek Biosciences subject to Rule 16b-3 | ||
Philippe Busque over six months ago Disposition of 2210 shares by Philippe Busque of Cytek Biosciences subject to Rule 16b-3 | ||
Philippe Busque over a year ago Disposition of 599 shares by Philippe Busque of Cytek Biosciences at 5.53 subject to Rule 16b-3 |
Cytek Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.0436) % which means that it has lost $0.0436 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0336) %, meaning that it created substantial loss on money invested by shareholders. Cytek Biosciences' management efficiency ratios could be used to measure how well Cytek Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of February 2, 2026, Return On Tangible Assets is expected to decline to -0.01. In addition to that, Return On Capital Employed is expected to decline to -0.04. At present, Cytek Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 124.4 M, whereas Total Assets are forecasted to decline to about 415.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Warren Machan | Avanos Medical | 59 | |
| Scot JD | Treace Medical Concepts | 51 | |
| Scot Elder | Treace Medical Concepts | 49 | |
| Gaetano Guglielmino | Treace Medical Concepts | 56 | |
| Michael CPA | Avanos Medical | 52 | |
| Rachel Osbeck | Treace Medical Concepts | N/A | |
| Elizabeth Jensen | Standard Biotools | 52 | |
| Joshua Copp | CeriBell | 39 | |
| Scott Blumberg | CeriBell | N/A | |
| Wouter Vlaanderen | Varex Imaging Corp | N/A | |
| Jamie Handler | Avanos Medical | N/A | |
| Terry Lubben | Treace Medical Concepts | 61 | |
| Mike Musgnug | Standard Biotools | N/A | |
| Sudhakar Varshney | Avanos Medical | 47 | |
| David MBA | Avanos Medical | 60 | |
| Jeremy Davis | Standard Biotools | N/A | |
| Sean Scanlan | Treace Medical Concepts | 44 | |
| Jeffrey Black | Standard Biotools | 55 | |
| BS MB | Standard Biotools | 64 | |
| Kimberley JD | Varex Imaging Corp | 56 | |
| Adam Taich | Standard Biotools | 48 | |
Management Performance
| Return On Equity | -0.0336 | ||||
| Return On Asset | -0.0436 |
Cytek Biosciences Leadership Team
Elected by the shareholders, the Cytek Biosciences' board of directors comprises two types of representatives: Cytek Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytek. The board's role is to monitor Cytek Biosciences' management team and ensure that shareholders' interests are well served. Cytek Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytek Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wenbin Jiang, CEO President | ||
| Todd Garland, Chief Officer | ||
| Ming Yan, CTO Director | ||
| Melik Ulusu, Senior Chain | ||
| Mark Edinger, VP Affairs | ||
| Allen Poirson, Senior Development | ||
| Connie Wedel, Chief Officer | ||
| Chris Williams, Chief Officer | ||
| Paul Goodson, Head Relations | ||
| William McCombe, Chief Officer | ||
| Philippe Busque, Senior Services | ||
| Patrik Jeanmonod, Head Analytics | ||
| Valerie JD, General Secretary | ||
| Paul Williams, Chief Officer |
Cytek Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cytek Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0336 | ||||
| Return On Asset | -0.0436 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 403.69 M | ||||
| Shares Outstanding | 127.86 M | ||||
| Shares Owned By Insiders | 9.27 % | ||||
| Shares Owned By Institutions | 63.84 % | ||||
| Number Of Shares Shorted | 6.39 M | ||||
| Price To Book | 1.69 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.735 | Earnings Share (0.11) | Revenue Per Share | Quarterly Revenue Growth 0.015 | Return On Assets |
Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.